Mir-452-3p: A Potential Tumor Promoter That Targets the CPEB3/EGFR Axis in Human Hepatocellular Carcinoma

Hui Tang, MD1,*, Jianwen Zhang, MD1,*, Zhenyu Yu, MD1, Linsen Ye, MM1, Kun Li, MM1, Fan Ding, MM1, Xiao Feng, MD1, and Wei Meng, MD1

Abstract

Purpose: We proposed to investigate the effects of miR-452-3p on the proliferation and mobility of hepatocellular carcinoma (HCC) cells by targeting cytoplasmic polyadenylation element binding protein 3/estimated glomerular filtration rate (CPEB3/EGFR) axis.

Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect miR-452-3p expression in 84 pairs of HCC tissues and adjacent tissues. Luciferase reporter assay was employed to examine the relationship between miR-452-3p and CPEB3. Microculture tetrazolium (MTT) assay, colony formation assay, flow cytometry detection, wound healing assay, and transwell assay were used to detect cell proliferation, cycle arrest, apoptosis, and mobility, respectively, in HCC, HepG2, and Huh-7. Western blot was used to detect protein expression levels in EGFR signaling pathway. Kaplan-Meier survival analysis was conducted to analyze the correlation between the miR-452-3p and CPEB3 expression levels and the survival of patients with HCC.

Results: MiRNA-452-3p was found significantly upregulated in 84 human HCC sample tissues and cells in comparison with adjacent tissues and normal liver epithelial cells (P < .01). Luciferase reporter assay demonstrated that CPEB3 was a direct target of miR-452-3p. Overexpression of miR-452-3p promoted cell proliferation and mobility and suppressed apoptosis. MiR-452-3p enhanced EGFR and phosphorylated AKT (pAKT) expression but inhibited p21 expression level.

Conclusion: MiR-452-3p promoted HCC cell proliferation and mobility by directly targeting the CPEB3/EGFR axis.

Keywords
HCC, MiR-452-3p, CPEB3, EGFR, proliferation

Received: March 6, 2017; Revised: June 13, 2017; Accepted: August 16, 2017.

Introduction

Hepatocellular carcinoma (HCC) is one of the most prevalent forms of liver cancer and is also the most common and deadly cancer in the world.1 Although modern researches have made significant progress in the early diagnosis and treatment of HCC, patients with HCC still have unfavorable prognoses. Currently, HCC is identified as the second leading cause of cancer-incurred mortality.2 The morbidity of HCC is closely related to the infection and proliferation of hepatitis C virus (HCV) or hepatitis B virus (HBV).3,4 Apart from that, obesity and heavy alcohol abuse could also increase the risk of HCC.5,6 Some research has shown that diverse epigenetic and genetic alterations might induce hepatocarcinogenesis,7 during which microRNAs (miRNAs) may play a crucial role in the pathogenesis of HCC.8 Previous studies have indicated that miRNAs presented aberrant expressions in HCC, including miR-106b, miR-26a, miR-659, and miR-372, all of which might regulate hepatocarcinogenesis by influencing cell proliferation, metastasis, and apoptosis.9,11 The relevant findings suggested that miRNAs participated in HCC pathogenesis. However, the role of miRNAs in HCC has not been yet fully elucidated, and hence, the deregulation of miRNAs in HCC needs to be further investigated.

1 Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University; Organ Transplantation Research Center of Guangdong Province, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
* Authors Hui Tang and Jianwen Zhang are first co-authors.

Corresponding Author:
Wei Meng, MD, Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University; Organ Transplantation Research Center of Guangdong Province, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Tianhe District, Guangzhou, Guangdong 510630, China.
Email: xiao_yue51833@126.com
The miRNAs are highly conserved small and noncoding RNA molecules that can transcriptionally or posttranscriptionally affect gene expression. It has been reported that miRNA alternation and aberrant expression are involved in the initiation and development of almost all types of cancers including HCC. The miRNAs have become a research focus, as they not only play essential roles in the diagnosis and treatment of diseases, but synthetic miRNAs resemble small-molecule therapeutics and offer a high degree of specificity at the genetic level. The miR-452 is located in human chromosome Xq28 and its aberrant expression is related to malignant biological properties of tumors. For example, the overexpression of miR-452 promotes tumorigenesis of HCC and inhibits metastasis of non-small-cell lung cancer (NSCLC) and tumorigengesis of gliomas. However, it remains unclear whether the expression of miR-452 is associated with the regulation of HCC cell proliferation, migration, and other tumor biological characteristics. It is the discovery of miRNAs and their downstream signaling pathways related to the proliferation and invasion of HCC and its prognostic significance that might provide a framework for better understanding the pathogenesis of the disease and offer more efficient clinical treatments.

Cytoplasmic polyadenylation element binding protein 3 (CPEB3) regulates translation by modulating cytoplasmic polyadenylation. The CPEB3 with aberrant expression has been found in several tumors. For example, Hansen et al revealed that CPEB3 was downregulated in cervical cancer, and a microarray analysis conducted by D’Ambrogio et al suggested that the CPEB3 expression level declined in HCC tissues compared with normal adjacent tissues. Furthermore, Zou et al demonstrated that miR-107 could promote tumor progression by targeting the CPEB3/estimated glomerular filtration rate (EGFR) axis. Although several studies have conducted certain research on CPEB3, few studies lay stress on the role of CPEB3 in HCC. From the databases of TargetScan, we found that CPEB3 has the binding site of miR-452, and thus, we hypothesized that there might exist an association among miR-452, CPEB3, and HCC.

In this study, we examined the expression levels of miR-452 and CPEB3 in HCC tissues and cell lines and analyzed the influence of the aberrantly expressed miR-452 on the proliferation and migration of HCC cells by targeting the CPEB3/EGFR axis. Our study aimed to investigate the clinical significance of miR-452 in the clinical diagnosis and prognosis and explore the therapeutic function of miR-452 in HCC and help find new therapeutic strategies for HCC treatment.

Materials and Methods

Clinical Sample Tissues

The HCC tissues (n = 84) were obtained from 84 patients during surgery in the Third Affiliated Hospital of Sun Yat-sen University between January 8, 2014, and January 8, 2016. Matched adjacent tissues were at least 2 cm distance from the borders of tumor location. All tissues were frozen in liquid nitrogen immediately and were stored at below 80°C. No patients had received any adjuvant treatments such as radiotherapy or chemotherapy before surgery. Written informed consent was obtained from each patient, and approval for the study was also obtained from the ethics committee of West China Hospital, Sichuan University.

Cell Lines

Human HCC cell lines including HepG2, Hep3B2.1-7, and Huh-7 as well as normal liver epithelial cells L-02 were purchased from the American Type Culture Collection (ATCC, Manassas, Virginia). All cells were placed in Dulbecco modified Eagle medium (DMED; Thermo Fisher Scientific, Waltham, Massachusetts) which contains 10% fetal bovine serum (FBS; HyClone, Logan, Utah), penicillin (100 U/mL), and streptomycin (100 mg/mL). All were stored at 37°C in a humidified atmosphere containing 5% CO2.

RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction

Total messenger RNAs (mRNAs) of stored human HCC tissues and cells were extracted using TRIZOL (Invitrogen, Carlsbad, California), and reverse-transcribed complementary DNA synthesis was performed with PrimeScript RT reagent kit (TaKaRa, Dalian, China). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using miSYBR-Green PCR kit (TransGen Biotech, China) following manufacturer’s protocol. U6 small nuclear RNA acted as an endogenous control for miR-452-3p normalization and β-actin was used as internal reference for CPEB3 normalization. The relative expression of miR-452-3p and CPEB3 was quantified using method. The primers designed for the study are listed in Table 1.

Western Blot Analysis

After 48 hours of transfection, cells were lysed in ice-cold radioimmunoprecipitation assay (RIPA) buffer (Solaibo, China) for total protein extraction. Concentrations of total protein were detected using BCA Protein Assay kit (Vigorous Bio-technology Beijing Co Ltd, Beijing, China). Proteins

### Table 1. Primer Sequences Designed for qRT-PCR.

| Primers          | MiR-452-3p F 5′-TGGAATGTAAGAAGTAAAGTG-3′ |
|------------------|---------------------------------------|
| CPEB3 F 5′-GAAAGGTAACACTACCCCTCCA-3′ | R 5′-CCAGGAAGCATTGTTAAGTG-3′ |
| U6 F 5′-CTCCTTGCAGCAGCA-3′ | R 5′-AACGCCTTCAGAATTTCGG-3′ |
| β-actin F 5′-TACCTCATGAAGATCTTCACC-3′ | R 5′-TTTCTTGAGGTCACAGAG-3′ |

Abbreviations: qRT-PCR, quantitative real-time polymerase chain reaction; CPEB3, cytoplasmic polyadenylation element binding protein 3; F, forward primers; R, reverse primers.
were then separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Hercules, California) then blocked for 1 hour with 5% nonfat milk at room temperature and incubated overnight with primary antibodies. The anti-CPEB3, anti-β-actin, anti-p21, anti-EGFR, anti-AKT, and anti-p-AKT antibodies used were purchased from Sigma-Aldrich Co Ltd (St. Louis, Missouri) and diluted at a ratio of 1:1000. After incubation with secondary antibodies (horseradish peroxidase–conjugated anti-IgG, 1:2000 dilution; Zhongshan Biology Company, Beijing), the protein bands were quantified with ImageJ software (National Institutes of Health, Bethesda, Maryland).

**Cell Transfection**

The amplification products of CPEB3 and pcDNA3.1 (Invitrogen) were connected to DNA ligase and amplified to construct a lentivirus vector. Wizard SV 96 Plasmid DNA Purification System (Promega, Madison, Wisconsin) was employed to harvest reconstruction plasmids. When cells (HepG2 and Huh-7) reached 80% confluence, cells were transfected with miR-452 mimic, miR-452-3p inhibitor, or reconstruction plasmids by Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer’s guides. All reagents including miR-452-3p mimic, miR-452-3p inhibitor, negative control (NC) mimic (NC for miR-452-3p mimic), and NC inhibitor (NC for miR-452-3p inhibitor) were synthesized and purified by Molbase Co Ltd, Shanghai, China.

**Luciferase Reporter Assay**

The 3’UTR target clone of psi-CHECKTM-2 was purchased from Promega; it contains renilla luciferase gene as internal control fused downstream to a firefly luciferase gene. The HepG2 cells were co-transfected with wild-type or mutant 3’-UTR sequence of CPEB3 and NC mimic or miR-452-3p mimic by Lipofectamine 2000 (Invitrogen) following manufacturer’s protocol. Luciferase activity was measured with Luc-Pair miR Luciferase Assay (GeneCopoeia, Rockville, Maryland).

**Microculture Tetrazolium Assay**

To test cell viability, cells were seeded in a 96-well plate, digested by trypsin, and suspended at final concentrations of 5 × 10^5 cells per well. At 24, 48, and 72 hours after transfection, 20 μL of microculture tetrazolium (MTT) reagent (Sigma) was added to each well and they were incubated for 4 hours at 37°C. Next, the medium culture was replaced by 150 μL of Annexin V-FITC (Annexin V-fluorescein isothiocyanate) and 5 μL of PI (Propidium Iodide) and 100 μL of RNA enzymes were added and the cells were incubated for 30 minutes in a dark room. Population in each phase was, respectively, measured with flow cytometry while apoptosis rates were analyzed using Cellquest software (Version 4.0; BD Biosciences, San Jose, California).

**Wound Healing Assay**

To test cell migration, cells were seeded in a 6-well plate at a density of 2 × 10^5 cells per well and allowed to grow to 80% confluence. Artificial wounds were then scratched using a sterile 200-mL micropipette tip. The scratched cells were washed with serum-free medium 3 times. Cells were subsequently incubated for 12 hours, and the migrated cells distant from the edge of the wounds were observed under an optical microscope (Nikon).

**Transwell Assay**

To test cell invasion, cells were lysed with trypsin, and the cell density was adjusted to 1 × 10^5 cells/mL. The upper chambers were coated with 150 μg of Matrigel (BD Biosciences, Bedford, Massachusetts), and the lower chambers was added with 500 μL of DMEM with 10% FBS. Cells were added into the upper chambers and incubated for 24 hours. Noninvading cells were removed and the invading cells were fixed in methanol, stained by crystal violet, and photographed under an optical microscope (Nikon).

**In Vivo Nude Mice Tumorigenesis Assay**

MiR-452-3p mimic, NC mimic, pcDNA3.1, and pcDNA3.1-CPEB3 transfected HepG2 cells were injected into the back of 4-week-old SCID (Severe Combined Immunodeficiency Disease) nude mice (n = 5 in each group). All mice were allowed to acclimatize to the new environment for 1 week before injection. Tumor volume was carefully measured every 3 days after it became visible according to the following formula: tumor volume (mm^3) = (length × width^2)/2.
Kaplan-Meier Survival Analysis

The 120-month follow-up data from 300 patients with HCC were obtained from TCGA databases. Kaplan-Meier survival analysis was performed to investigate the correlation between miR-452-3p and CPEB3 expression levels and the survival of patients with HCC.

Statistical Analysis

All data were analyzed with GraphPad Prism 6.0 (GraphPad, San Diego, California), and each experiment was repeated 3 times. Results were presented as mean ± standard deviation. Statistical differences between different groups were either analyzed with 2-tailed Student t test or 1-way analysis of variance (ANOVA) if the data met the normal distribution. Otherwise, the Mann-Whitney or Kruskal-Wallis test was used. P < .05 was considered statistically significant.

Results

MiR-452-3p was Upregulated in HCC Sample Tissues and Cell Lines

The miR-452-3p expression in 84 pairs of sample tissues was detected using qRT-PCR. It was observed that miR-452-3p was significantly upregulated in human HCC sample tissues and cell lines.

- **Figure 1.** The miR-452-3p was significantly upregulated in human HCC sample tissues and cell lines. A, Relative expression level of miR-452-3p in 84 paired HCC tissues and adjacent normal tissues as detected by RT-PCR. **P < .01** vs adjacent tissues. B, Prognosis of patients with HCC in terms of miR-452-3p expression was calculated with Kaplan-Meier survival analysis. C, Relative expression level of miR-452-3p in HCC cell lines and normal liver epithelial cell line was detected by qRT-PCR. *P < .05** vs L-02 group. HCC indicates hepatocellular carcinoma; qRT-PCR, quantitative real-time polymerase chain reaction.
Kaplan-Meier survival analysis was then performed to explore the potential correlation between miR-452-3p expression and overall survival rates in patients using follow-up data from TCGA. The results shown in Figure 1B demonstrate that patients with higher miR-452-3p expression were more likely to have a poorer prognosis than those with lower miR-452-3p expression (P < .05). To further verify the result in HCC cells, miR-452-3p expression in normal liver epithelial cell L-02 and HCC cell lines including HepG2, Hep3B2.1-7, and Huh-7 were also measured. Not surprisingly, miR-452-3p was upregulated in HCC cells (P < .05; Figure 1C). The HepG2 and Huh-7 cells were selected for the following experiments.

The Effect of miR-452-3p on HCC Cell Proliferation

The HepG2 and Huh-7 cells were transfected with either miR-452-3p mimic or inhibitor in order to increase or decrease the miR-452-3p expression, respectively. The MTT and colony formation assays were performed to estimate HCC cell viability as well as proliferation in vitro. As shown in Figure 2A, ectopic overexpression of miR-452-3p significantly enhanced cell viability in comparison with the control and NC groups, while inhibition of miR-452-3p reduced cell viability (P < .05). The results were also substantiated in colony formation assay (P < .01; Figure 2B). In addition, the simulative effect of miR-452-3p on HCC cell growth was confirmed by tumorigenicity...
in vivo. After 21 days, the tumor volume and the weight of nude mice injected with miR-452-3p mimic transfected cells were much larger than those injected with miR-452-3p NC transfected cells (P < .01; Figure 2C-E).

The Effect of miR-452-3p in HCC Cell Cycle and Apoptosis

The overexpression of miR-452-3p led to more HCC cells arrested at S and G2/M phases compared with NC group, while inhibition of miR-452-3p led to more HepG2 cells arrested at G0/G1 phase (P < .05; Figure 3A). Flow cytometry results for cell apoptosis detection were consistent with other results. We observed that HepG2 and Huh-7 cells transfected with miR-452-3p mimic resulted in a significant decrease in apoptosis rate when compared with the NC group, while transfection of miR-452-3p inhibitor significantly increased cell apoptosis rate (P < .01; Figure 3B).

The Effect of miR-452-3p on HCC Cell Mobility

Wound healing assay and transwell assay were performed to detect HCC cell migration and invasion, respectively. For migration detection, the cells migrating the wound area increased dramatically in those transfected with miR-452-3p mimic compared with the NC group, whereas the number of migrated cells significantly decreased in those transfected with miR-452-3p inhibitor (P < .05; Figure 4A).

For invasion detection, the number of cells invading through the membrane in miR-452-3p mimic group was more than that
in the NC group, whereas the number of cells was relatively fewer in the miR-452-3p inhibitor group (P < .05; Figure 4B).

**MiR-452-3p Directly Targeted CPEB3**

To further detect the target function of miR-452-3p, CPEB3 might be considered a target for miR-452-3p from databases of TargetScan. The potential binding sites of miR-452-3p was complementary to the 3'UTR of CPEB3 mRNA (Figure 5A). The luciferase activity was remarkably decreased in cells co-transfected with miR-452-3p mimic and CPEB3-wt (P < .05), while it was rarely changed in those co-transfected with miR-452-3p mimic and CPEB3-mut (P > .05; Figure 5B). Western blot was performed to further verify that the overexpression of miR-452-3p inhibited the expression of CPEB3, while the inhibition of miR-452-3p promoted the expression of CPEB3 (Figure 5C).

**The Overexpression of CPEB3 Suppressed HCC Cell Proliferation, Mobility, and Induced Cell Apoptosis**

The qRT-PCR was used to measure the relative expression of CPEB3 mRNA in 84 pairs of sample tissues and cell lines. Likewise, CPEB3 was downregulated in tumor sample tissues and cell lines compared with adjacent tissues and the normal liver epithelial cell line, respectively (P < .05; Figure 6A, B). The results showed that the expression of CPEB3 was negatively correlated with those of miR-452-3p (R = −0.476;
Furthermore, Kaplan-Meier survival analysis revealed that, in general, patients with higher expression of CPEB3 were more likely to have a positive prognosis than those with lower expressions of CPEB3 ($P < .05$; Figure 6D).

The MTT and colony formation assays suggested that the overexpression of CPEB suppressed HCC cell proliferation significantly ($P < .01$), while the effects of pcDNA3.1-CPEB were antagonized by miR-452-3p mimic ($P > .05$; Figure 6E, F). Meanwhile, the tumor volume and weight of nude mice injected with pcDNA3.1-CPEB were smaller than those of the control group ($P < .01$; Figure 6G to I).

In addition, flow cytometry demonstrated that overexpression of CPEB3 induced cell cycle arrest and apoptosis. Transfection of pcDNA3.1-CPEB3 led to more cells arrested at G0/G1 phase ($P < .05$), while the effects of pcDNA3.1-CPEB3 were antagonized by miR-452-3p mimic ($P > .05$; Figure 7A). Moreover, CPEB3 overexpression resulted in a significant increase in apoptosis rate ($P < .01$; Figure 7B). Wound healing assay and transwell assay further demonstrated that the overexpression of CPEB3 suppressed HepG2 and Huh-7 cell migration and invasion ($P < .01$; Figure 8A; $P < .05$; Figure 8B).

**MiR-452-3p Modified the Downstream EGFR Pathway**

To detect the function of miR-452-3p, we further examine the expression of relative proteins in the EGFR pathway. The results in Figure 9 showed that miR-452-3p promoted EGFR and phosphorylated AKT (pAKT) expression and inhibited p21 expression ($P < .01$). Meanwhile, the effect of CPEB3 on protein expression was opposite to that of miR-452-3p ($P < .01$). The simultaneous overexpression of miR-452-3p and CPEB3 resulted in a similar result with the control group ($P > .05$).

**Discussion**

The HCC is the most common type of liver cancer, with a high fatality rate worldwide due to late diagnosis and lack of effective therapies. Various genetic and epigenetic factors influence the development of liver carcinogenesis, and miRNAs may play important roles in the pathogenesis of HCC. In our study, qRT-PCR results indicated that levels of miR-452-3p increased dramatically in HCC tissues and cells compared with adjacent tissues and normal liver cells, respectively. This was also consistent with the findings of Wang et al and Zheng et al. As for the effect of miR-452-3p on HCC prognosis, Zheng et al discovered that the patients with HCC with overexpressed miR-452-3p showed poor overall survival rates, as was confirmed in our study. The above results suggested that miR-452-3p might play a critical role in HCC as a carcinogenic gene and a biomarker of poor prognosis.

Therefore, our study focused on miR-452-3p's impact on the biological properties of HCC cells. The results revealed that the upregulation of miR-452-3p expression significantly improved the proliferation, invasion, and migration abilities of HCC cells, while downregulation of miR-452-3p weakened these properties. Meanwhile, measurement by flow cytometry indicated that miR-452-3p regulated HCC cell apoptosis and cell cycles. Transfection with miR-452-3p mimic decreased cell apoptosis rates and increased the ratio of cells in S or...
Figure 6. The overexpression of CPEB3 suppressed HCC cell proliferation in vitro and in vivo. A, B, The results of qRT-PCR showed that CPEB3 was frequently downregulated in human HCC tissues and cell lines. **P < .01 vs adjacent tissues; *P < .05 vs normal human epithelial cells (L-02). C, The expression of CPEB3 in tissue samples was negatively correlated with the expression of miR-452-3p. D, The prognosis of HCC patients in terms of CPEB3 expression was calculated with Kaplan-Meier survival analysis. E, The results of MTT assay showed that the overexpression of CPEB3 significantly decreased HepG2 and Huh-7 cell proliferation while the mixed group saw a reduced effect of miR-452-3p on cells compared with the control group. *P < .05 vs control group; **P < .01 vs control group. F, The effect of CPEB3 on cell growth was further verified by colony formation assay. **P < .01 vs control group. G to I, The tumors harvested from nude mice were statistically analyzed to demonstrate the growth rate of the tumors in different groups. TW/BW indicates tumor weight/body weight. **P < .01 vs pcDNA3.1 group. CPEB3 indicates cytoplasmic polyadenylation element binding protein 3; HCC, hepatocellular carcinoma; MTT, microculture tetrazolium.
G2/M stage, while transfection of miR-452-3p inhibitor led to greater apoptosis rates and GO/G1 arrest.

For further exploration, we investigated the potential molecular mechanisms of miR-452-3p in regulating HCC cells. Up to now, some target genes of miR-452-3p have already been identified, such as CDKN1B, BMI1, and Sox7. Based on our bioinformatic analysis, we demonstrated that CPEB3 was one of the miR-452-3p target genes in HCC cells. The results of dual luciferase assay and Western blot indicated that miR-452-3p was directly related to the 3’UTR region of CPEB3 and negatively affected its expression, which also indicated that CPEB seemed to be a critical part of the downstream mechanisms of miR-452-3p in the carcinogenesis of HCC.

The CPEB3, a member of CPEB family, plays the role in regulating translation by modulating cytoplasmic polyadenylation. It has been found that CPEB3 was aberrantly expressed in sporadic colorectal cancers and human papillomavirus (HPV)-positive cervical cancers. In our study, we discovered that CPEB3 was significantly downregulated in HCC tissues and cells. As for its regulative functions in the initiation and development of HCC, the results of relevant assays suggested that the overexpression of CPEB3 inhibited HCC cell

Figure 7. The overexpression of CPEB3 regulated cell cycle arrest and apoptosis. A, Cell cycle distribution was measured by PI staining and flow cytometry. B, CPEB3-induced HepG2 cell apoptosis. *P < .05 vs control group; **P < .01 vs control group. CPEB3 indicates cytoplasmic polyadenylation element binding protein 3.
proliferation, migration, invasion, and apoptosis and led to G0/G1 arrest, which is akin to the impact of downregulated expression of miR-452-3p on HCC cells. The CPEB3/EGFR axis regulated by miR-452-3p might be involved in HCC pathogenesis. The EGFR family of receptor signaling pathways is closely associated with cancer cell proliferation and survival, especially in lung cancer where approximately 10% of patients have a remarkable clinical reaction to EGFR-TKIs. Chen-Dan Zou et al demonstrated that CPEB negatively regulated the expressions of EGFR and downstream proteins in neurons. Based on these previous findings, we hypothesized that miR-452-3p, a potential HCC promoter, regulated the CPEB3/EGFR signal pathway and affected the protein expression of CPEB3, EGFR, and related downstream proteins. Furthermore, Western blot results indicated that the miR-452-3p induced the downregulation of

**Figure 8.** The overexpression of CPEB3 suppressed HepG2 cell mobility. A, B, The results of wound healing assay and transwell assay showed that the overexpression of CPEB3 suppressed HepG2 cell mobility. *P < .05 vs control group; **P < .01 vs control group. CPEB3 indicates cytoplasmic polyadenylation element binding protein 3.
CPEB3 levels and increased the expression of EGFR, a regulating pivot in HCC.\(^{28}\) In addition, the downstream proteins of CPEB3/EGFR signaling p21 and AKT/pAKT were modulated as expected. The negative effect of miR-452-3p on p21, an important cell cycle checkpoint molecule,\(^ {29}\) might be involved in miR-452-3p’s regulation of HCC cell cycles. The discovery

**Figure 9.** MiR-452-3p modified the downstream signaling pathway of EGFR. The expressions of CPEB3, p21, EGFR, AKT, pAKT, and β-actin in different groups were detected by Western blot. **\(P < .01\) vs NC mimic group; ## \(P < .01\) vs pcDNA3.1 group. CPEB3 indicates cytoplasmic polyadenylation element binding protein 3; EGFR, estimated glomerular filtration rate; NC, negative control.**
of miR-452-3p/CPEB3 signaling pathway has provided a new assumption for the pathogenesis of HCC and might be conducive to the development of potential HCC therapeutic strategies.

In summary, miR-452-3p was overexpressed in HCC tissues and cells and was identified as a potential HCC carcinogenic gene. Upregulation of miR-452-3p expression negatively influenced the CPEB3/EGFR axis, leading to the increase in proliferation, invasion, migration, and anti-apoptosis abilities of HCC cells and the decrease in cell arrest in G0/G1. The findings would lay a foundation for a more intensive study of the molecular mechanisms and could help develop more effective and safer HCC therapeutic strategies.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed the following financial support for the research, authorship, and/or publication of this article: This study was supported by National Natural Science Foundation of China (No. 81370575, 81470870, 81370555, 81372243), the Natural Science Foundation of Guangdong Province (No. 2015A030313038), the Science and Technology Program of Guangzhou (2014J4100183, 201400000001-3, 158100076), and the Science and Technology Program of Guangdong Province (2014A020211015).

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-E386. doi: 10.1002/ijc.29210; 10.1002/ijc.29210.

2. El-Serag HB. Hepatocellular carcinoma. *N Engl J Med*. 2011; 365(12):1118-1127. doi: 10.1056/NEJMra101683; 10.1056/NEJMra101683.

3. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. *J Clin Gastroenterol*. 2013; 47(suppl):S2-S6. doi: 10.1097/MCG.0b013e3182872f29.

4. Shlomi A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. *Semin Cancer Biol*. 2014;26:78-88. doi: 10.1016/j.semcancer.2014.01.004.

5. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. *Clin Gastroenterol Hepatol*. 2005;3(11):1150-1159.

6. Loomba R, Yang HI, Su J, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. *Am J Epidemiol*. 2013;177(4):333-342. doi: 10.1093/aje/kws252; 10.1093/aje/kws252.

7. Dhasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000Res*. 2016;5. First Published: May 12, 2016; Latest Published; May 12, 2016. doi: 10.12688/f1000research.6946.1.

8. Zheng Q, Sheng Q, Jiang C, et al. MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B. *Mol Cell Biochem*. 2014;389(1-2):187-195. doi: 10.1007/s11010-013-1940-z.

9. Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. *Mol Cell Biochem*. 2013;375(1-2): 23-30. doi: 10.1007/s11010-012-1521-6.

10. Zhang L, Yang L, Liu X, et al. MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. *Hepatology*. 2013;57(5):1919-1930. doi: 10.1002/hep.26162; 10.1002/hep.26162.

11. Yau WL, Lam CS, Ng L, et al. Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process. *PLoS One*. 2013;8(3):e57882. doi: 10.1371/journal.pone.0057882.

12. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. *Gastroenterology*. 2012;142(7):1431-1443. doi: 10.1053/j.gastro. 2012.04.007.

13. Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. *Cell*. 2009;137(6):1005-1017. doi: 10.1016/j.cell.2009.04.021.

14. Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer*. 2006;6(11):857-866. doi: 10.1038/nrc1997.

15. Chang IF, Szick-Miranda K, Pan S, Bailey-Serres J. Proteomic characterization of evolutionarily conserved and variable proteins of Arabidopsis cytosolic ribosomes. *Plant Physiol*. 2005;137(3): 848-862. doi: 10.1104/pp.104.053637.

16. He Z, Xia Y, Pan C, et al. Up-regulation of MiR-452 inhibits metastasis of non-small cell lung cancer by regulating BMI1. *Cell Physiol Biochem*. 2015;37(1):387-398. doi: 10.1159/000430362.

17. Liu L., Chen K, Wu J, et al. Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas. *Clin Cancer Res*. 2013;19(13):3429-3438. doi: 10.1158/1078-0432.CCR-12-3794.

18. Phelan JT. A new method of artery graft anastomosis; an experimental study. *Surgery*. 1958;44(6):990-993.

19. Hansen CN, Ketabi Z, Rosenstierne MW, Palle C, Boesen HC, Norrild B. Expression of CPEB, GAPDH and U6snRNA in cervical and ovarian tissue during cancer development. *APMIS*. 2009;117:53-59. doi: 10.1111/j.1600-0463.2008.00015.x.

20. D’Ambrogio A, Nagaoka K, Richter JD. Translational control of cell growth and malignancy by the CPEBs. *Nat Rev Cancer*. 2013;13(4):283-290. doi: 10.1038/nrc3485.

21. Zou CD, Zhao WM, Wang XN, et al. MicroRNA-107: a novel promotor of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma. *Oncotarget*. 2016;7(1):266-278. doi: 10.18632/oncotarget.5689.

22. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69-90. doi: 10.3322/caac.20107.

23. Wang Y, Toh HC, Chow P, et al. MicroRNA-224 is up-regulated in hepatocellular carcinoma. *Oncotarget*. 2013;4(12):13644-13654. doi: 10.18632/oncotarget.12389.

24. Zheng Z, Liu J, Yang Z, et al. MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving...
Wnt/beta-catenin signaling pathway. Oncotarget. 2016;7(19):28000-28012. doi: 10.18632/oncotarget.8584.

25. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61(suppl 2):1-13.

26. Zou Q, Zhan P, Lv T, Song Y. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis. Transl Lung Cancer Res. 2015;4(6):792-796. doi: 10.3978/j.issn.2218-6751.2015.12.09.

27. Zou CD, Zhao WM, Wang XN, et al. MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma. Oncotarget. 2016;7:266-278. doi: 10.18632/oncotarget.5689.

28. Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol. 2014;49(1):9-23. doi: 10.1007/s00535-013-0907-x.

29. Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 2008;28(7):2167-2174. doi: 10.1128/MCB.01977-07.